1613372-28-3

Basic information

• Product Name: C₄₄H₆₀N₄O₁₁S₂Si
• Synonyms: C₄₄H₆₀N₄O₁₁S₂Si
• CAS NO: 1613372-28-3
• Molecular Weight: 913.198
• Mol File: 1613372-28-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₄₄H₆₀N₄O₁₁S₂Si(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₄H₆₀N₄O₁₁S₂Si(1613372-28-3)
• EPA Substance Registry System: C₄₄H₆₀N₄O₁₁S₂Si(1613372-28-3)

Safety Data

• Hazardous Substances Data: 1613372-28-3(Hazardous Substances Data)

Upstream product

• 1612761-46-2 C₁₆H₃₄O₄Si 
• 1612761-45-1 C₁₂H₂₆O₄Si 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1609174-44-8 C₂₇H₃₅N₃O₅S₂ 
• 485800-26-8 N-tert-butoxycarbonyl cystamine 
• 1613372-40-9 salsalate 
• 1613372-39-6 salsalate 
• 552-94-3 2-hydroxy-benzoic acid, 2-carboxyphenyl ester 
• 1112-33-0 D-pantoic acid 
• 1609174-45-9 C₁₂H₂₅N₃O₃S₂ 
• 1613372-27-2 C₃₂H₃₇NO₉Si 
• 1613372-26-1 C₃₆H₄₅NO₉Si 
• 1613372-60-3 2-((2-(nicotinoyloxy)benzoyl)oxy)benzoic acid 

Downstream Products

• 1613372-29-4 C₃₉H₅₂N₄O₉S₂Si 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.